{"casebody": {"status": "ok", "data": "<html><body><casebody firstpage=\"22\" lastpage=\"22\" xmlns=\"http://nrs.harvard.edu/urn-3:HLS.Libr.US_Case_Law.Schema.Case_Body:v1\">\n<parties id=\"p-1\">H. (T.)<br/> v.<br/> NOVARTIS PHARMACEUTICALS CORPORATION.</parties>\n<docketnumber id=\"p-2\">No. S233898.</docketnumber>\n<court id=\"p-3\">Supreme Court of California</court>\n<decisiondate id=\"p-4\">June 8, 2016.</decisiondate>\n\n\n<judges id=\"p-7\">CANTIL-SAKAUYE, C.J., CHIN, CORRIGAN, LIU, CU\u00c9LLAR, and KRUGER, JJ., concur.</judges>\n<opinion type=\"majority\"><p id=\"p-5\">The applications to appear as counsel pro hac vice are granted. The petition for review is granted. The issue to be briefed and argued is limited to the following: May the brand name manufacturer of a pharmaceutical drug that divested all ownership interest in the drug be held liable for injuries caused years later by another manufacturer's generic version of that drug?</p><p id=\"p-6\">WERDEGAR, J., was recused and did not participate.</p></opinion>\n</casebody></body></html>"}}